Literature DB >> 25520855

Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.

Min Luo1, Li-Wu Fu1.   

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown dramatic effects against that tumors harboring EGFR activating mutations in the EGFR intracytoplasmic tyrosine kinase domain and resulted in cell apoptosis. Unfortunately, a number of patients ultimately developed resistance by multiple mechanisms. Thus, elucidation of the mechanism of resistance to EGFR-TKIs can provide strategies for blocking or reversing the situation. Recent studies suggested that redundant kinase activation plays pivotal roles in escaping from the effects of EGFR-TKIs. Herein, we aimed to characterize several molecular events involved in the resistance to EGFR-TKIs mediated by redundant kinase activation.

Entities:  

Keywords:  EGFR; redundant kinase activation; resistance to EGFR-TKIs

Year:  2014        PMID: 25520855      PMCID: PMC4266699     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  159 in total

1.  The CD95 receptor: apoptosis revisited.

Authors:  Marcus E Peter; Ralph C Budd; Julie Desbarats; Stephen M Hedrick; Anne-Odile Hueber; M Karen Newell; Laurie B Owen; Richard M Pope; Juerg Tschopp; Harald Wajant; David Wallach; Robert H Wiltrout; Martin Zörnig; David H Lynch
Journal:  Cell       Date:  2007-05-04       Impact factor: 41.582

2.  Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Authors:  Carlton L Schwab; Diana P English; Dana M Roque; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Roberta Nicoletti; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2014-08-12       Impact factor: 5.482

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Vienna Ludovini; Fortunato Bianconi; Lorenza Pistola; Rita Chiari; Vincenzo Minotti; Renato Colella; Dario Giuffrida; Francesca Romana Tofanetti; Annamaria Siggillino; Antonella Flacco; Elisa Baldelli; Daniela Iacono; Maria Grazia Mameli; Antonio Cavaliere; Lucio Crinò
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

5.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Authors:  B Arnulf; S Lecourt; J Soulier; B Ternaux; M-Noelle Lacassagne; A Crinquette; J Dessoly; A-K Sciaini; M Benbunan; C Chomienne; J-P Fermand; J-P Marolleau; J Larghero
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

7.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

8.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

9.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

10.  High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

Authors:  Yixuan Gong; Evelyn Yao; Ronglai Shen; Aviva Goel; Maria Arcila; Julie Teruya-Feldstein; Maureen F Zakowski; Stanley Frankel; Martin Peifer; Roman K Thomas; Marc Ladanyi; William Pao
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more
  18 in total

1.  AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.

Authors:  Xiaoyu Chen; Danrui Cui; Yanli Bi; Jianfeng Shu; Xiufang Xiong; Yongchao Zhao
Journal:  Cell Cycle       Date:  2018-09-19       Impact factor: 4.534

2.  Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways.

Authors:  Zhenzhen Zhang; Weixing Yu; Min Zheng; Xinhua Liao; Jichuang Wang; Dayun Yang; Wenxian Lu; Long Wang; Sheng Zhang; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Mol Carcinog       Date:  2019-04-26       Impact factor: 4.784

3.  Tracing the Anti-cancer Mechanism of Pleurotus osteratus by the Integrative Approach of Network Pharmacology and Experimental Studies.

Authors:  Singh Shreya; Dulla Naveen Kumar; Debadatta Mohapatra; Shivani Jaiswal; Gaurav Gopal Naik; Santosh Kumar Guru; Ashish Kumar Agarwal; Senthil Raja Ayyannan; Alakh N Sahu
Journal:  Appl Biochem Biotechnol       Date:  2022-09-06       Impact factor: 3.094

4.  A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Authors:  Luke S McLean; Tessa A Morris; Ann Gramza; Stephen Liu; Saad A Khan; A Dimitrios Colevas; Tillman Pearce; Danny Rischin
Journal:  Invest New Drugs       Date:  2022-04-18       Impact factor: 3.651

Review 5.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

6.  Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature.

Authors:  Anna Ferrazzi; Irene Russo; Giulia Pasello; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2015-11-19       Impact factor: 2.447

7.  Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.

Authors:  ChunLing Dai; ShaoLin Ma; Fang Wang; HongYun Zhao; XingPing Wu; ZhenCong Huang; ZheSheng Chen; Kenneth To; LiWu Fu
Journal:  Oncotarget       Date:  2015-07-10

8.  Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Authors:  Concetta Di Mauro; Ada Pesapane; Luigi Formisano; Roberta Rosa; Valentina D'Amato; Paola Ciciola; Alberto Servetto; Roberta Marciano; Roberta Clara Orsini; Francesca Monteleone; Nicola Zambrano; Gabriella Fontanini; Adele Servadio; Giuseppe Pignataro; Lucia Grumetto; Antonio Lavecchia; Dario Bruzzese; Antonino Iaccarino; Giancarlo Troncone; Bianca Maria Veneziani; Nunzia Montuori; Sabino De Placido; Roberto Bianco
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

9.  Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.

Authors:  Wei Ma; Yanhong Kang; Lanlan Ning; Jie Tan; Hanping Wang; Yi Ying
Journal:  Exp Ther Med       Date:  2017-07-28       Impact factor: 2.447

Review 10.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

Authors:  Ramesh Butti; Sumit Das; Vinoth Prasanna Gunasekaran; Amit Singh Yadav; Dhiraj Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.